Multimodal Imaging Signatures of the Biological Mechanisms Underlying Neurodegeneration in Multiple Sclerosis

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Nov 21, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how advanced imaging techniques can help us understand the biological processes behind neurodegeneration in people with Multiple Sclerosis (MS). While treatments have improved for the inflammatory aspects of MS, finding ways to protect the nerves from damage and slow down disability is still a significant challenge. The researchers, led by Prof. Stankoff, are using a combination of PET scans and MRI to create detailed maps that show things like ongoing nerve repair and inflammation. They hope to identify patterns that could predict how MS will progress in the future.

To participate in this study, you need to be an adult with MS who has been part of specific prior studies for at least eight years. You also need to be willing to undergo MRI scans, which may not be possible for everyone due to certain health conditions or if you have specific implants. If you join the study, you can expect to undergo advanced imaging tests that will help researchers learn more about your condition and could contribute to developing better treatments for MS. It's important to know that participants will be informed if any serious issues are found during the MRI scans.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Multiple Sclerosis Patient already enrolled in one of those 3 protocols since 8 years or more: INFLASEP, FLUMATEP 1-2 or SHADOWTEP
• • Adult patient
• • Affiliation to a social security scheme or beneficiary of such a scheme (Except "Aide Médicale d'Etat")
• • Consent obtained
• Exclusion Criteria:
• • Any reasons, which does not allow to perform MRI, including claustrophobia, the implant of a pace maker or the presence of an intra-ocular foreign body (a contra- indication questionnaire will be filled in beforehand)
• • Pregnancy, breast-feeding, lack of efficient contraception
• • Current symptoms of severe or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary or cardiac disease, or any other chronic neurological diseases
• • Unwillingness to be informed in case of abnormal MRI (with a significant medical anomaly)
• • Enrolment in another interventional study protocol for the duration of his or her participation without physician's agreement
• • Patient under legal protection